Skip to main content

Oliveto Joseph's Form 4 filing

Milestone Pharmaceuticals Inc. (MIST) · filed Jan 28, 2026

Accession no.
0001437782-26-000004
Filed
Jan 28, 2026
Trade date
Dec 12, 2025-Jan 26, 2026
Filing delay
47 daysLate
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $375.3K. It was filed 47 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Oliveto JosephCIK 0001437782Director, Officer (President and CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 12, 2025Common SharesAGrant or awardAcquired+280,000–F2–583,721Direct
Dec 15, 2025Common SharesSSaleDisposed−133,054$2.32F4−$308,685.28450,667Direct
Jan 26, 2026Common SharesMOption exerciseAcquired+66,600–F5–517,267Direct
Jan 26, 2026Common SharesSSaleDisposed−34,523$1.93F4−$66,629.39482,744Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 12, 2025Common SharesAGrant or awardAcquired+280,000$0.00$0280,000Direct
Jan 26, 2026Common SharesMOption exerciseDisposed−66,600$0.00$0199,800Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Each PSU represents a contingent right to receive one common share.

Referenced by the price of 1 transaction in Table I.

F4

The price reported is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 2 transactions in Table I.

F5

Each RSU represents a contingent right to receive one common share.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)